Stock Analysis
- Bulgaria
- /
- Healthcare Services
- /
- BUL:SFT
Sopharma Trading AD Full Year 2023 Earnings: EPS: лв0.88 (vs лв0.26 in FY 2022)
Sopharma Trading AD (BUL:SFT) Full Year 2023 Results
Key Financial Results
- Revenue: лв1.68b (up 14% from FY 2022).
- Net income: лв30.0m (up 239% from FY 2022).
- Profit margin: 1.8% (up from 0.6% in FY 2022). The increase in margin was driven by higher revenue.
- EPS: лв0.88 (up from лв0.26 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Sopharma Trading AD shares are up 1.8% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Sopharma Trading AD that you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Sopharma Trading AD is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BUL:SFT
Sopharma Trading AD
Sopharma Trading AD operates as a trading company in the pharmaceutical sector in Bulgaria and Serbia.
Solid track record with excellent balance sheet.